International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 206-211
| Back | Table of Contents | PDF | Mail to Author | |
Impact of Replacing Low Dose Cyclophosphamide with Fludarabine in Children with Acute Myeloid Leukemia Undergoing Transplantation During First Complete Remission
Vedat UYGUN1, Gulsun KARASU2, Koray YALCIN3, Seda OZTURKMEN4, Hayriye DALOGLU5, Safiye Suna CELEN3, Volkan HAZAR2, Akif YESILIPEK4
1Istinye University, Faculty of Medicine, MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit
2MedicalPark Göztepe Hospital, Department of Pediatric Bone Marrow Transplantation Unit
3Bahcesehir University, Faculty of Medicine, MedicalPark Göztepe Hospital, Department of Pediatric Bone Marrow Transplantation Unit
4MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit
5Antalya Bilim University Faculty of Health Sciences, MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit
Busulfan (BU)-based myeloablative conditioning is a standard conditioning regimen for children with AML; however, it is not clear yet which combination of cyclophosphamide (CY) and fludarabine (FLU) is most effective. We performed a study to compare the results of BUCY120 and BU-FLU in pediatric patients with AML in CR1 undergoing allo-HSCT from matched sibling donors. With the combination of BU, 15 patients were given 120 mg/kg of CY, and 12 patients were given 150 mg/m2 of FLU, respectively, in the condition regimen. Patients treated with BUFLU relapsed less than those treated with BUCY120 (p= 0.03). Moreover, these patients engrafted platelets earlier than the BUCY120 administered patients (p= 0.03). The frequency of complications in both groups was comparable. There was no significant difference in survival analysis between the groups. BUFLU has a low toxicity profile, making it a reasonable choice for children with AML in CR1 with low risk and a lower relapse frequency compared to BUCY120.
Vedat UYGUN1, Gulsun KARASU2, Koray YALCIN3, Seda OZTURKMEN4, Hayriye DALOGLU5, Safiye Suna CELEN3, Volkan HAZAR2, Akif YESILIPEK4
1Istinye University, Faculty of Medicine, MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit
2MedicalPark Göztepe Hospital, Department of Pediatric Bone Marrow Transplantation Unit
3Bahcesehir University, Faculty of Medicine, MedicalPark Göztepe Hospital, Department of Pediatric Bone Marrow Transplantation Unit
4MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit
5Antalya Bilim University Faculty of Health Sciences, MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit
Busulfan (BU)-based myeloablative conditioning is a standard conditioning regimen for children with AML; however, it is not clear yet which combination of cyclophosphamide (CY) and fludarabine (FLU) is most effective. We performed a study to compare the results of BUCY120 and BU-FLU in pediatric patients with AML in CR1 undergoing allo-HSCT from matched sibling donors. With the combination of BU, 15 patients were given 120 mg/kg of CY, and 12 patients were given 150 mg/m2 of FLU, respectively, in the condition regimen. Patients treated with BUFLU relapsed less than those treated with BUCY120 (p= 0.03). Moreover, these patients engrafted platelets earlier than the BUCY120 administered patients (p= 0.03). The frequency of complications in both groups was comparable. There was no significant difference in survival analysis between the groups. BUFLU has a low toxicity profile, making it a reasonable choice for children with AML in CR1 with low risk and a lower relapse frequency compared to BUCY120.
| Back | Table of Contents | PDF | Mail to Author | |